GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Compound class:
Antibody
Comment: PRTH-101 (Incendia Therapeutics) is a humanized monoclonal antibody that binds to the extracellular domain of discoidin domain-containing receptor 1 (DDR1) [1]. It is proposed to disrupt the collagen-based physical barrier in the tumour extracellular matrix, thus permitting improved CD8+ T cell infiltration in to tumours.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use  |
| PRTH-101 is an anti-tumour clinical candidate. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05753722 | A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies | Phase 1 Interventional | Incendia Therapeutics | ||
